JACC:二尖瓣手术后起搏器的植入会增加患者死亡风险

2019-05-21 不详 MedSci原创

与单独的二尖瓣手术(MVS)相比,MVS伴房颤消融术后的永久性起搏器植入率(PPM)会更高。本研究的目的旨在评估PPM在MVS伴房颤消融术患者中的发生率及临床预后。本研究纳入了243名无PPM植入的房颤患者,随机分成MVS组(n=117)和MVS联合射频消融组(n=126),消融组又随机分为肺静脉分离组(PVI,n=62)和双向迷宫组(n=64),分析结果显示,有35名(14.4%)患者在术后第一

与单独的二尖瓣手术(MVS)相比,MVS伴房颤消融术后的永久性起搏器植入率(PPM)会更高。本研究的目的旨在评估PPM在MVS伴房颤消融术患者中的发生率及临床预后。

本研究纳入了243名无PPM植入的房颤患者,随机分成MVS组(n=117)和MVS联合射频消融组(n=126),消融组又随机分为肺静脉分离组(PVI,n=62)和双向迷宫组(n=64),分析结果显示,有35名(14.4%)患者在术后第一年接受了PPM植入,其中MVS组的PPM植入率为7.7%,MVS+PVI组植入率为16.1%,MVS+双向迷宫组植入率为25%。射频消融、多瓣手术和纽约心功能III/IV级是PPM植入的独立危险因素。PPM植入不会增加患者30天再住院率(HR: 1.43; 95% CI: 0.50-4.05; p = 0.50),需要PPM的植入与更高的1年死亡率相关(HR: 3.21; 95% CI: 1.01-10.17; p = 0.05)。

研究结果显示,房颤消融术、多瓣膜手术和纽约心功能III/IV级是永久性起搏器植入的独立危险因素。二尖瓣手术后PPM的植入可增加1年死亡率。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854391, encodeId=61fa185439115, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 19:00:00 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952157, encodeId=8439195215e11, content=<a href='/topic/show?id=f11b2390577' target=_blank style='color:#2F92EE;'>#二尖瓣手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23905, encryptionId=f11b2390577, topicName=二尖瓣手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Dec 09 23:00:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983623, encodeId=d89f1983623c9, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 03 13:00:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255860, encodeId=376912558601a, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318847, encodeId=cc63131884ec3, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326212, encodeId=b3da1326212f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463246, encodeId=cfc1146324681, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520586, encodeId=9f3e1520586fb, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
    2020-03-30 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854391, encodeId=61fa185439115, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 19:00:00 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952157, encodeId=8439195215e11, content=<a href='/topic/show?id=f11b2390577' target=_blank style='color:#2F92EE;'>#二尖瓣手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23905, encryptionId=f11b2390577, topicName=二尖瓣手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Dec 09 23:00:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983623, encodeId=d89f1983623c9, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 03 13:00:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255860, encodeId=376912558601a, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318847, encodeId=cc63131884ec3, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326212, encodeId=b3da1326212f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463246, encodeId=cfc1146324681, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520586, encodeId=9f3e1520586fb, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854391, encodeId=61fa185439115, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 19:00:00 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952157, encodeId=8439195215e11, content=<a href='/topic/show?id=f11b2390577' target=_blank style='color:#2F92EE;'>#二尖瓣手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23905, encryptionId=f11b2390577, topicName=二尖瓣手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Dec 09 23:00:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983623, encodeId=d89f1983623c9, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 03 13:00:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255860, encodeId=376912558601a, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318847, encodeId=cc63131884ec3, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326212, encodeId=b3da1326212f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463246, encodeId=cfc1146324681, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520586, encodeId=9f3e1520586fb, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854391, encodeId=61fa185439115, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 19:00:00 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952157, encodeId=8439195215e11, content=<a href='/topic/show?id=f11b2390577' target=_blank style='color:#2F92EE;'>#二尖瓣手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23905, encryptionId=f11b2390577, topicName=二尖瓣手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Dec 09 23:00:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983623, encodeId=d89f1983623c9, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 03 13:00:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255860, encodeId=376912558601a, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318847, encodeId=cc63131884ec3, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326212, encodeId=b3da1326212f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463246, encodeId=cfc1146324681, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520586, encodeId=9f3e1520586fb, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854391, encodeId=61fa185439115, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 19:00:00 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952157, encodeId=8439195215e11, content=<a href='/topic/show?id=f11b2390577' target=_blank style='color:#2F92EE;'>#二尖瓣手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23905, encryptionId=f11b2390577, topicName=二尖瓣手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Dec 09 23:00:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983623, encodeId=d89f1983623c9, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 03 13:00:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255860, encodeId=376912558601a, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318847, encodeId=cc63131884ec3, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326212, encodeId=b3da1326212f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463246, encodeId=cfc1146324681, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520586, encodeId=9f3e1520586fb, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
    2019-05-23 HNYYM
  6. [GetPortalCommentsPageByObjectIdResponse(id=1854391, encodeId=61fa185439115, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 19:00:00 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952157, encodeId=8439195215e11, content=<a href='/topic/show?id=f11b2390577' target=_blank style='color:#2F92EE;'>#二尖瓣手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23905, encryptionId=f11b2390577, topicName=二尖瓣手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Dec 09 23:00:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983623, encodeId=d89f1983623c9, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 03 13:00:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255860, encodeId=376912558601a, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318847, encodeId=cc63131884ec3, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326212, encodeId=b3da1326212f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463246, encodeId=cfc1146324681, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520586, encodeId=9f3e1520586fb, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1854391, encodeId=61fa185439115, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 19:00:00 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952157, encodeId=8439195215e11, content=<a href='/topic/show?id=f11b2390577' target=_blank style='color:#2F92EE;'>#二尖瓣手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23905, encryptionId=f11b2390577, topicName=二尖瓣手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Dec 09 23:00:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983623, encodeId=d89f1983623c9, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 03 13:00:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255860, encodeId=376912558601a, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318847, encodeId=cc63131884ec3, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326212, encodeId=b3da1326212f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463246, encodeId=cfc1146324681, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520586, encodeId=9f3e1520586fb, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
    2019-05-23 wwzzly
  8. [GetPortalCommentsPageByObjectIdResponse(id=1854391, encodeId=61fa185439115, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 30 19:00:00 CST 2020, time=2020-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952157, encodeId=8439195215e11, content=<a href='/topic/show?id=f11b2390577' target=_blank style='color:#2F92EE;'>#二尖瓣手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23905, encryptionId=f11b2390577, topicName=二尖瓣手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Dec 09 23:00:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983623, encodeId=d89f1983623c9, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 03 13:00:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255860, encodeId=376912558601a, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318847, encodeId=cc63131884ec3, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326212, encodeId=b3da1326212f2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463246, encodeId=cfc1146324681, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520586, encodeId=9f3e1520586fb, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Thu May 23 01:00:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
    2019-05-23 jiyangfei

相关资讯

JACC:钙离子通道阻滞剂可改善桡动脉冠脉搭桥患者预后

本研究的目的旨在评估慢性钙离子通道阻滞剂(CCB)对桡动脉(RA)冠脉搭桥中期临床预后和血管生成的影响。本研究纳入了732名RA冠脉搭桥患者,其中502名接受了CCB治疗,经过平均60个月时间的随访,CCB治疗组和非CCB治疗组患者的第36、72和108个月的累积主要不良心血管事件(MACE)发生率分别是 3.7% vs. 9.3%, 13.4% vs. 17.6%, 16.8% vs. 20.5

罗沙司他全球III期临床研究证实其心血管安全性

近日,阿斯利康公布其罗沙司他全球III期临床研究心血管(CV)安全性汇总分析结果。罗沙司他是全球首个低氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI),也是首个在中国获批上市的肾性贫血口服新药,已于2018年12月获得国家药品监督管理局(NMPA)的上市批准,用于慢性肾脏病透析患者的贫血治疗。本次试验评估了罗沙司他在非透析(NDD)、初始非稳定透析(ID)和稳定透析的慢性肾脏病(CKD)患者人群中贫

JACC:一种可预测10年心衰风险模型的开发

目前尚无心衰的一级预防策略,且缺少心衰的风险预测工具。本研究的目的旨在推导出发展为心衰的10年风险方程。本研究纳入了1985-2000年30-79岁的无心血管疾病的参与者作为合并队列(PC),随机分为两组进行推导和内部验证,并在2个另外的队列中对模型方程进行验证。最终共有11771名对象纳入PC,女性占58%,黑种人占22%,平均年龄52±12岁,有1339名患有心衰。心衰风险的预测模型中包括年龄

JACC:残余炎症可增加PCI术后患者不良心脑血管事件风险

目前,对于残余炎症风险(RIR)对接受冠脉介入治疗(PCI)且基线低密度脂蛋白胆固醇(LDL-C)≤70mg/dl患者的影响尚不清楚。本研究的目的旨在评估PCI术后高RIR的发生率和影响。本研究纳入了2009-2016年基线LDL-C≤70mg/dl并进行了高敏C反应蛋白(hsCRP)评估的PCI患者,高RIR定义为hsCRP >2 mg/l。患者根据RIR状态分为持续性低RIR组、RIR减

Stroke:房颤与脑形态学的关系

房颤于认知下降和痴呆有关,独立于临床发生的卒中。其确切的机制尚未被完全阐明,但是房颤患者可以合并亚临床脑梗死(subclinical cerebral infarctions,SCI)、脑微梗死、慢性脑低灌注、炎症,并且共享血管危险因素比如高血压和糖尿病。脑 MRI 研究发现了脑形态学改变和认识功能受损之间的关系。 基于社区人群研究发现,白质高信号(white mater hyperintensi

盘点:JACC五月第二期研究一览

1.利伐沙班联合阿司匹林可减少肾功能不全患者的不良事件风险